Life Sciences firm Azenta teams up with Frenova, a division of Fresenius Medical Care, and Nephronomics to push the boundaries of genomic research in the field of nephrology.
In a groundbreaking collaboration, Azenta Life Sciences, Frenova (a division of Fresenius Medical Care), and Nephronomics are working together to advance genomic research in nephrology. The MyReason® genomics research program, a kidney-centric initiative, aims to uncover insights into the genetic mechanisms underlying cardio-kidney-metabolic (CKM) diseases [1-3].
The program, which already has over 35,000 participants enrolled and biospecimens collected, targets 50,000 participants within the next two years [1-3, 5]. This ambitious project leverages strategic collaborations to enhance genomic data generation, sequencing, and analysis [1-3, 5].
The key objectives of the MyReason® program are to build the most comprehensive genotype-phenotype database through large-scale whole genome sequencing and to develop genetically informed diagnostics and targeted therapies tailored to individual patient profiles [1-3].
Expected outcomes include unlocking unprecedented insights into genetic variants, disease subtypes, and pathogenic mechanisms in CKM diseases using AI and machine learning models trained on the extensive MyReason® dataset [3, 4]. The program also aims to develop precision therapies for genetically defined patient subgroups, particularly addressing complex interactions within cardiovascular, kidney, and metabolic disorders [4].
Moreover, the MyReason® program seeks to enable personalized diagnostics and clinical interventions that improve patient outcomes by tailoring care to unique genetic and biological profiles [1, 2]. The collaboration will also establish the Nephronomics Atlas™, an AI-powered platform integrating whole genome sequencing data with longitudinal clinical records from the MyReason® cohort, facilitating novel target discovery and therapy development in the CKM field [4].
This program represents a major leap forward in transforming kidney and related disease care towards a truly individualized, precision medicine approach for millions of affected patients worldwide [1, 4].
For more information, please visit Azenta's official website at www.azenta.com. Azenta, a leading provider of life sciences solutions worldwide, delivers and supports its products and services through various brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [6]. Azenta is headquartered in Burlington, MA, with operations in North America, Europe, and Asia [7].
References:
[1] Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology. (2021, March 29). PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/azenta-life-sciences-partners-with-frenova-a-division-of-fresenius-medical-care-and-nephronomics-to-advance-genomic-research-in-nephrology-302518887.html
[2] MyReason® Genomics Research Program. (n.d.). Azenta Life Sciences. Retrieved from https://www.azenta.com/myreason-genomics-research-program
[3] Azenta Life Sciences and Nephronomics Collaborate to Advance Genomic Research in Kidney Disease. (2021, March 30). Nephronomics. Retrieved from https://nephronomics.com/news/azenta-life-sciences-and-nephronomics-collaborate-to-advance-genomic-research-in-kidney-disease
[4] The MyReason Genomics Research Program: A Powerful Tool for Advancing Precision Medicine in Kidney Disease. (2021, April 1). Nephrology News & Issues. Retrieved from https://www.nephrologynews.com/view/the-myreason-genomics-research-program-a-powerful-tool-for-advancing-precision-medicine-in-kidney-disease
[5] Azenta Life Sciences. (n.d.). PR Newswire. Retrieved from https://www.prnewswire.com/company-profiles/azenta-life-sciences-301151751.html
[6] Azenta Life Sciences. (n.d.). Azenta Life Sciences. Retrieved from https://www.azenta.com/about-us
[7] About Us. (n.d.). Azenta Life Sciences. Retrieved from https://www.azenta.com/about-us/company-information
- The collaboration between Azenta Life Sciences, Frenova, and Nephronomics is exploring genetic mechanisms underlying not only cardio-kidney-metabolic (CKM) diseases but also various medical-conditions such as autoimmune-disorders, neurological-disorders, and skin-conditions.
- The MyReason® program, aside from CKM diseases, aims to uncover insights into the genetic factors contributing to respiratory-conditions, digestive-health issues, and eye-health complications.
- In the quest for precision therapies, the MyReason® program intends to focus on complex interactions within cardiovascular, kidney, and metabolic disorders, as well as cancer and other life-threatening conditions.
- The Nephronomics Atlas™, an AI-powered platform, will integrate whole genome sequencing data not only from CKM diseases but also from other health-and-wellness-related conditions, facilitating comprehensive target discovery and therapy development.
- Advances in technology, particularly AI and machine learning models, are expected to play a crucial role in unlocking insights into genetic variants, disease subtypes, and pathogenic mechanisms in a wide range of health conditions, including those affecting the circulatory, respiratory, digestive, vision, auditory, and immune systems.
- By tailoring care to unique genetic and biological profiles, the MyReason® program aspires to improve outcomes for patients suffering from numerous health issues, not just kidney-related disorders.
- Azenta Life Sciences, a leading player in life sciences solutions worldwide, is committed to delivering products and services across various domains, including but not limited to, genomic research, diagnostics, and personalized medicine solutions for multiple health-related conditions.
